JPH10507352A - ｒｅｐ陰性ＡＡＶ変異体の調製およびそれに使用可能な細胞 - Google Patents

ｒｅｐ陰性ＡＡＶ変異体の調製およびそれに使用可能な細胞

Info

Publication number: JPH10507352A
Authority: JP; Japan
Prior art keywords: aav; rep; negative; dna; mutant
Prior art date: 1994-10-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP8512845A

Other languages

English (en)

Japanese (ja)

Inventor

ヘルシェル，クリスティーナ

ビュルクレ，アレキサンデル

クラインシュミット，ユルゲン

ヘーレル，マルクス

ハウゼン，ハラルドツアー

シャンボーン，ピエール

ハイルブロン，レジーネ

Original Assignee

ドイチェスクレブスフォルシュンクスツェントルムスチフトゥングデスエッフェントリヒェンレヒツ

マックス−プランク−ゲゼルシャフトツアーフェルデルンクデルヴィッセンシャフテンエー．ファー．

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-10-13

Filing date

1995-10-12

Publication date

1998-07-21

1994-10-13 Priority claimed from DE19944436664 external-priority patent/DE4436664A1/de

1994-10-13 Priority claimed from DE19944436665 external-priority patent/DE4436665C2/de

1995-10-12 Application filed by ドイチェスクレブスフォルシュンクスツェントルムスチフトゥングデスエッフェントリヒェンレヒツ, マックス−プランク−ゲゼルシャフトツアーフェルデルンクデルヴィッセンシャフテンエー．ファー． filed Critical ドイチェスクレブスフォルシュンクスツェントルムスチフトゥングデスエッフェントリヒェンレヒツ

1998-07-21 Publication of JPH10507352A publication Critical patent/JPH10507352A/ja

Status Pending legal-status Critical Current

Links

238000002360 preparation method Methods 0.000 title abstract description 5
239000013613 expression plasmid Substances 0.000 claims abstract description 13
108090000623 proteins and genes Proteins 0.000 claims description 34
102000004169 proteins and genes Human genes 0.000 claims description 28
108020004414 DNA Proteins 0.000 claims description 20
238000000034 method Methods 0.000 claims description 16
241000700605 Viruses Species 0.000 claims description 11
230000035772 mutation Effects 0.000 claims description 9
230000010076 replication Effects 0.000 claims description 7
101150066583 rep gene Proteins 0.000 claims description 5
241000701161 unidentified adenovirus Species 0.000 claims description 4
101150044789 Cap gene Proteins 0.000 claims description 3
230000037430 deletion Effects 0.000 claims description 3
238000012217 deletion Methods 0.000 claims description 3
241001529453 unidentified herpesvirus Species 0.000 claims description 3
102000003676 Glucocorticoid Receptors Human genes 0.000 claims description 2
108090000079 Glucocorticoid Receptors Proteins 0.000 claims description 2
230000010307 cell transformation Effects 0.000 claims description 2
230000037431 insertion Effects 0.000 claims description 2
238000003780 insertion Methods 0.000 claims description 2
238000002955 isolation Methods 0.000 claims description 2
238000006467 substitution reaction Methods 0.000 claims description 2
208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 49
241000702421 Dependoparvovirus Species 0.000 description 35
210000004027 cell Anatomy 0.000 description 35
101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 description 6
101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 4
101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 3
241000701109 Human adenovirus 2 Species 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
239000013598 vector Substances 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
229960003957 dexamethasone Drugs 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
239000002245 particle Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000000527 sonication Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
239000013607 AAV vector Substances 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
241000883306 Huso huso Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
241000701945 Parvoviridae Species 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
SDIXRDNYIMOKSG-UHFFFAOYSA-L disodium methyl arsenate Chemical compound [Na+].[Na+].C[As]([O-])([O-])=O SDIXRDNYIMOKSG-UHFFFAOYSA-L 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000037433 frameshift Effects 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000010257 thawing Methods 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP8512845A 1994-10-13 1995-10-12 ｒｅｐ陰性ＡＡＶ変異体の調製およびそれに使用可能な細胞 Pending JPH10507352A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DE19944436664 DE4436664A1 (de)	1994-10-13	1994-10-13	Bereitstellung von rep-negativen AAV-Mutanten und hierfür verwendbare Zellen
DE4436665.5		1994-10-13
DE4436664.7		1994-10-13
DE19944436665 DE4436665C2 (de)	1994-10-13	1994-10-13	Bereitstellung von rep-negativen AAV-Mutanten und hierfür verwendbare Zellen
PCT/DE1995/001429 WO1996012010A1 (de)	1994-10-13	1995-10-12	Bereitstellung von rep-negativen aav-mutanten und hierfür verwendbare zellen

Publications (1)

Publication Number	Publication Date
JPH10507352A true JPH10507352A (ja)	1998-07-21

Family

ID=25941026

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP8512845A Pending JPH10507352A (ja)	1994-10-13	1995-10-12	ｒｅｐ陰性ＡＡＶ変異体の調製およびそれに使用可能な細胞

Country Status (4)

Country	Link
EP (1)	EP0785991A1 (de)
JP (1)	JPH10507352A (de)
CA (1)	CA2202664A1 (de)
WO (1)	WO1996012010A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5866552A (en) *	1996-09-06	1999-02-02	The Trustees Of The University Of Pennsylvania	Method for expressing a gene in the absence of an immune response
EP0931158A1 (de) *	1996-09-06	1999-07-28	The Trustees Of The University Of Pennsylvania	Indutierbare methode zur herstellung von rekombinanten adeno-assoziierten viren mittels t7 polymerase
IT1297074B1 (it) *	1997-11-21	1999-08-03	Angeletti P Ist Richerche Bio	Forme ormone-dipendenti delle proteine rep del virus adeno-associato (aav-2), sequenze di dna codificanti per esse, vettori che le

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU8200191A (en) *	1990-07-09	1992-02-04	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	High efficiency packaging of mutant adeno-associated virus using amber suppressions
WO1995013365A1 (en) *	1993-11-09	1995-05-18	Targeted Genetics Corporation	Generation of high titers of recombinant aav vectors
PT728214E (pt) *	1993-11-09	2004-11-30	Ohio Med College	Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
US5693531A (en) *	1993-11-24	1997-12-02	The United States Of America As Represented By The Department Of Health And Human Services	Vector systems for the generation of adeno-associated virus particles

1995
- 1995-10-12 JP JP8512845A patent/JPH10507352A/ja active Pending
- 1995-10-12 CA CA 2202664 patent/CA2202664A1/en not_active Abandoned
- 1995-10-12 EP EP95934604A patent/EP0785991A1/de not_active Withdrawn
- 1995-10-12 WO PCT/DE1995/001429 patent/WO1996012010A1/de not_active Ceased

Also Published As

Publication number	Publication date
EP0785991A1 (de)	1997-07-30
CA2202664A1 (en)	1996-04-25
WO1996012010A1 (de)	1996-04-25

Publication	Publication Date	Title
US9567607B2 (en)	2017-02-14	Adeno-associated virus serotype I nucleic acid sequences, vectors and host cells containing same
EP1127150B1 (de)	2007-05-16	Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
AU774706B2 (en)	2004-07-08	Methods for large-scale production of recombinant AAV vectors
US6458587B2 (en)	2002-10-01	Helper virus-free AAV production
JP4473346B2 (ja)	2010-06-02	組換えａａｖビリオン産生における使用のための補助機能
CA2221293C (en)	2012-09-18	Helper virus-free aav production
AU4805800A (en)	2000-11-10	Methods, compositions, and cells for encapsidating recombinant vectors in aav particles
CN114127296B (zh)	2024-10-25	Ube3a基因和表达盒及其应用
EP1359223A2 (de)	2003-11-05	WtAAV-freie Herstellung von rekombinanten AAV
US20020177222A1 (en)	2002-11-28	Replication competent AAV helper functions
JPH10507352A (ja)	1998-07-21	ｒｅｐ陰性ＡＡＶ変異体の調製およびそれに使用可能な細胞
US7148341B2 (en)	2006-12-12	AAV DNA comprising helper virus sequences
EP1845163A2 (de)	2007-10-17	Adeno-assoziierte Virus-Serotyp-I-Nukleinsäuresequenzen und diese enthaltende Vektoren und Wirtszellen
US6783972B1 (en)	2004-08-31	Methods for large-scale production of recombinant AAV vectors
CN119552222B (zh)	2025-08-08	腺相关病毒视网膜细胞嗜性衣壳突变体及应用
Smith et al.	1998	AAV Vectors: General Characteristics and Potential for Use in the Central Nervous System
JP2009077737A (ja)	2009-04-16	組換えａａｖビリオン産生における使用のための補助機能
Smith et al.	1997	for Use in the Central Nervous System